All News PepGen Inc.

Equities

PEPG

US7133171055

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
13.16 ^USD	-3.59%		-6.07%	+93.53%

15/05	PepGen Q1 Loss Narrows	MT
14/05	PepGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PepGen Q1 Loss Narrows	15/05	MT
PepGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	15/05	GL
PepGen : Corporate Deck – May 2024	08/05	PU
PepGen to Participate in Upcoming Investor Conferences	14/03	GL
PepGen to Participate in Upcoming Investor Conferences	14/03	AQ
PepGen Says Potential Duchenne Muscular Dystrophy Treatment Gets FDA Orphan Drug, Rare Pediatric Disease Designations	13/03	MT
PepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease Designations	13/03	DJ
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	13/03	GL
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	13/03	AQ
Wedbush Trims PepGen's PT to $20 From $21, Incorporates Offering, Adjusts Share Count Assumptions; Maintains Outperform Rating	07/03	MT
Transcript : PepGen Inc., Q4 2023 Earnings Call, Mar 06, 2024	07/03
PepGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	07/03	GL
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	07/03	AQ
PepGen Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03	CI
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	04/03	GL
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	04/03	AQ
PepGen Inc. Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	04/03	CI
PepGen Says FDA Grants Fast Track Designation to Potential Myotonic Dystrophy Type 1 Treatment	20/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News PepGen Inc.

Equities

PEPG

US7133171055

All News

Filters